The FINANCIAL -- Leverkusen, Germany, September 29, 2011 -- Bayer AG announced today that the double blind, placebo controlled Phase III ATLAS ACS TIMI 51 clinical trial of Rivaroxaban plus standard therapy has met its primary efficacy endpoint, showing a statistically significant reduction in the rate of events for the primary composite endpoint of cardiovascular death, myocardial infarction and stroke in patients with ACS, compared to standard therapy plus placebo.

For the primary safety endpoint, defined as major bleeding events not associated with Coronary Artery Bypass Graft surgery according to the TIMI-classification, there was a statistically significant increase in such events in patients receiving Rivaroxaban versus placebo.

It is intended to present these data as soon as possible at a forthcoming scientific congress as well as to file for market authorization by the end of this year.

Related Stories

• New Phase 3 data for Tradjenta tablets in black or African American patients with type 2 diabetes
• Innovative public-private collaboration launches to tackle antibiotic research
• Phase II Trial Used Ambulatory Blood Pressure Monitoring to Evaluate Blood Pressure